Merck’s pembrolizumab demonstrates improvement in distant metastasis
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
To address the preventive & primary healthcare delivery gaps in India
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
This agreement is in addition to the $92 million filling line expansion announced in November 2021
New logo reflects Thyrocare’s transformation since 1996 to its current leading position at the cutting edge of Diagnostic services
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
Subscribe To Our Newsletter & Stay Updated